Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.
The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.
A Concentra subsidiary is expected to commence a tender offer by May 15.
The transaction is anticipated to close by mid-2025, Kronos Bio said.
Shares of Kronos were down nearly 23% in recent trading.
Price: 0.69, Change: -0.20, Percent Change: -22.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.